Annals of medicine and surgery (2012)Dec 11, 2025

Stem cell therapy as a new approach to reverse type 1 diabetes

Regenerative Health Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jan 7, 2026

Abstract

Up to 40% of participants in early-phase clinical trials achieved partial insulin independence through .

Stem cell therapy may regenerate insulin-producing beta cells and modulate immune responses.
Types of stem cells investigated include embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, and pancreatic progenitor cells.
Recent trials reported a 20-30% reduction in exogenous insulin requirements among some participants.
C-peptide levels, indicating endogenous insulin production, increased for 6-12 months in certain cases.
Challenges such as scalable production, long-term engraftment, and achieving immune tolerance remain.

Simplified

(T1DM) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, necessitating lifelong insulin therapy. Despite advancements in glucose monitoring and insulin delivery, current treatments remain palliative and fail to address the root autoimmune pathology or restore endogenous insulin production. has emerged as a promising curative approach due to its dual capacity to regenerate beta cells and modulate immune responses by suppressing autoreactive immune cells and promoting immune tolerance. This review explores the various types of stem cells under investigation - embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, and pancreatic progenitor cells - highlighting their unique advantages and limitations. We delve into mechanisms of action including cell differentiation protocols, immune protection strategies such as encapsulation, and the synergistic use of gene editing to enhance graft survival. Recent preclinical successes and early-phase clinical trials have demonstrated partial insulin independence in up to 40% of participants, with others showing 20-30% reductions in exogenous insulin requirements and measurable increases in C-peptide levels sustained for 6-12 months. However, challenges remain in achieving scalable production, long-term engraftment, and immune tolerance. As research continues to overcome these barriers, stem cell therapy holds transformative potential to shift T1DM treatment from management to functional cure.

Key numbers

40%

Partial Insulin Independence

Achieved by participants in early-phase clinical trials.

20-30%

Reduction in Insulin Requirements

Observed in some patients during clinical trials.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Stem cell therapy as a new approach to reverse type 1 diabetes

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week: